Mizuho Reaffirms “Buy” Rating for Horizon Pharma (HZNP)
“We reiterate our Buy rating on Krystexxa momentum and upcoming teprotumumab Phase III data (expected 2Q:19).”,” Mizuho’s analyst wrote.
Several other research firms have also weighed in on HZNP. BidaskClub raised Horizon Pharma from a buy rating to a strong-buy rating in a research report on Friday, August 10th. Cantor Fitzgerald reissued a buy rating and set a $21.00 price target on shares of Horizon Pharma in a research report on Thursday, September 13th. Morgan Stanley upped their price target on Horizon Pharma from $16.00 to $24.00 and gave the company an equal weight rating in a research report on Friday, August 17th. Jefferies Financial Group upped their price target on Horizon Pharma from $21.00 to $23.00 and gave the company a buy rating in a research report on Thursday, August 9th. Finally, Cowen reissued a buy rating and set a $25.00 price target on shares of Horizon Pharma in a research report on Thursday, August 9th. Five equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Horizon Pharma presently has an average rating of Buy and an average price target of $23.58.
Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings results on Wednesday, November 7th. The biopharmaceutical company reported $0.65 earnings per share for the quarter, beating the consensus estimate of $0.50 by $0.15. The firm had revenue of $325.30 million for the quarter, compared to analyst estimates of $311.84 million. Horizon Pharma had a positive return on equity of 27.24% and a negative net margin of 18.70%. Horizon Pharma’s quarterly revenue was up 19.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.26 earnings per share. Equities analysts forecast that Horizon Pharma will post 1.34 earnings per share for the current year.
In other news, EVP Geoffrey M. Curtis sold 9,904 shares of the stock in a transaction dated Thursday, August 16th. The stock was sold at an average price of $20.63, for a total transaction of $204,319.52. Following the transaction, the executive vice president now owns 28,767 shares of the company’s stock, valued at approximately $593,463.21. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 3.90% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the company. First Quadrant L P CA boosted its stake in Horizon Pharma by 189.1% during the 3rd quarter. First Quadrant L P CA now owns 6,117 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 4,001 shares during the period. Ladenburg Thalmann Financial Services Inc. boosted its stake in Horizon Pharma by 74.4% during the 1st quarter. Ladenburg Thalmann Financial Services Inc. now owns 9,091 shares of the biopharmaceutical company’s stock valued at $128,000 after purchasing an additional 3,877 shares during the period. Quantitative Systematic Strategies LLC bought a new stake in Horizon Pharma during the 2nd quarter valued at approximately $172,000. Strs Ohio boosted its stake in Horizon Pharma by 74.2% during the 2nd quarter. Strs Ohio now owns 10,800 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 4,600 shares during the period. Finally, Inspirion Wealth Advisors LLC bought a new stake in Horizon Pharma during the 2nd quarter valued at approximately $207,000. 87.24% of the stock is currently owned by institutional investors and hedge funds.
Horizon Pharma Company Profile
Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.
Recommended Story: 52-Week High/Low Prices For Stock Selection
Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.